Canaccord Genuity analyst Austin Moeller has maintained their bullish stance on CBUS stock, giving a Buy rating on August 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Austin Moeller has given his Buy rating due to a combination of factors that highlight Cibus’s strategic positioning and financial management. The company has demonstrated a significant reduction in operating expenses, particularly through its restructuring efforts, which are aimed at focusing resources on the commercialization of its weed management traits and sustainable ingredients. This financial prudence is seen as a positive step in preserving capital amidst challenging funding conditions in the agriculture sector.
Austin Moeller also notes the promising future revenue streams from Cibus’s biofragrance products and the anticipated regulatory advancements in the EU for gene editing technologies. The company’s efforts to commercialize its sustainable ingredients are on track, with expectations for revenue growth starting in 2025 and scaling significantly in subsequent years. Additionally, the progress in regulatory harmonization for gene editing, particularly in the EU and UK, further supports the potential for Cibus’s products to achieve market success. These factors collectively contribute to the positive outlook and the Buy rating for Cibus’s stock.
In another report released on August 15, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.